What happened
Heath Secretary Robert F. Kennedy Jr. said Tuesday he had ordered a "coordinated wind-down" of mRNA vaccine development programs at the government's biodefense agency. The decision canceled or modified 22 projects worth nearly $500 million, primarily for work on vaccines and therapeutics for respiratory viruses including influenza, H5N1 bird flu and Covid-19, according to the Health and Human Services Department.
Who said what
Kennedy said in a video statement that the Biomedical Advanced Research and Development Authority (BARDA) would "replace the troubled mRNA programs" with "safer, broader vaccine strategies, like whole-virus vaccines" — a century-old technique he has also recently criticized, The New York Times said. As the "pandemic showed us," Kennedy added, incorrectly, "mRNA vaccines don't perform well against viruses that infect the upper respiratory tract."
By "issuing this wildly incorrect statement," Kennedy is "demonstrating his commitment to his long-held goal of sowing doubts about all vaccines," Brown University pandemic preparedness expert Jennifer Nuzzo told the Times. The funding cuts followed "months of pressure from anti-vaccine activists" to "pull all mRNA shots off the market," The Washington Post said.
Vaccine and pandemic preparedness experts "expressed horror" at Kennedy's decision, which delivered a "crippling blow" to America's "capacity to develop vaccines during the next pandemic" or another biological threat, Stat News said. "I don't think I've seen a more dangerous decision in public health in my 50 years in the business," University of Minnesota infectious disease expert Mike Osterholm told The Associated Press.
What next?
Researchers worldwide are also "exploring" mRNA's "use for cancer immunotherapies," with notable success treating colorectal cancer, said the AP. HHS said Tuesday that "other uses of mRNA technology within the department are not impacted by this announcement." But "if you're a smaller biotech or just a smaller manufacturer," these mRNA cuts "really can discourage a company from making further investments," said Richard Hughes IV, a vaccine law teacher at George Washington University, to the Post.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
What are blue slips and why does Trump want to end them?Today's Big Question The practice lets senators block a president's judge and prosecutor nominees
-
What are 'freakosystems' and how are they affecting the planet?The explainer Ecosystems are changing permanently
-
'The question is what it does for the ecosystem'Instant Opinion Opinion, comment and editorials of the day
-
A new subtype of diabetes was found and it may require different treatmentUnder the radar It is prevalent in Black Africans and Americans
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
How China is battling the chikungunya virusUnder The Radar Thousands of cases of the debilitating disease have been found in the country
-
The truth about sunscreenThe Explainer The science behind influencer claims that sun cream is toxic
-
Why the FDA wants to restrict kratom-related productsIn the Spotlight The compound is currently sold across the United States
-
Food may contribute more to obesity than exerciseUnder the radar The devil's in the diet
-
Babies born using 3 people's DNA lack hereditary diseaseUnder the Radar The method could eliminate mutations for future generations
-
Not just a number: how aging rates vary by countryThe explainer Inequality is a key factor
